A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo

Chemical Research in Toxicology

Volumn 18, Issue 9, 2005, Pages 1384-1394

  Gardner, Iain ^a,c   Popović, Marija ^a   Zahid, Nasir ^a   Uetrecht, Jack P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CLOZAPINE; GLUTATHIONE; HYDROGEN PEROXIDE; MYELOPEROXIDASE; N ACETYLLYSINE; OPC 1533; PHORBOL 12 ACETATE 13 MYRISTATE; PIPERANOMETOZINE; PROCAINAMIDE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; COVALENT BOND; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG METABOLISM; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NEUTROPHIL; NONHUMAN; PROTEIN MODIFICATION; RAT;

ANIMALS; BONE MARROW; CLOZAPINE; FEMALE; HEMOCYANIN; HUMANS; IMMUNE SERA; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; NEUTROPHILS; PHORBOL ESTERS; PROCAINAMIDE; QUINOLINES; RATS; TEMPERATURE;

EID: 25444527734     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx050095o     Document Type: Article

References (32)

1. Uetrecht, J. P. (1992) The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab. Rev. 24, 299-366.
2. Kaufman, D. W., Kelly, J. P., Jurgelon, J. M., Anderson, T., Issaragrisil, S., Wiholm, B. E., Young, N. S., Leaverton, P., Levy, M., and Shapiro, S. (1996) Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur. J. Haematol. Suppl. 60, 23-30.
3. Alvir, J. M., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., and Schaaf, J. A. (1993) Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. 329, 162-167.
4. Guest, I., Sokoluk, B., MacCrimmon, J., and Uetrecht, J. (1998) Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 131, 53-65.
5. Pisciotta, A. V. (1973) Immune and toxic mechanisms in drug-induced agranulocytosis. Semin. Hematol. 10, 279-310.
6. Pumford, N. R., and Halmes, N. C. (1997) Protein targets of xenobiotic reactive intermediates. Annu. Rev. Pharmacol. Toxicol. 37, 91-117.
7. Matzinger, P. (1994) Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045.
8. Seguin, B., and Uetrecht, J. (2003) The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol. 3, 235-242.
9. Furusawa, S., Ohashi, Y., and Asanoi, H. (1996) Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety. J. Clin. Pharmacol. 36, 477-481.
10. Guest, I., and Uetrecht, J. (1999) Drugs that induce neutropenia/ agranulocytosis may target specific components of the stromal cell extracellular matrix. Med. Hypotheses 53, 145-151.
11. Honigfeld, G., Arellano, F., Sethi, J., Bianchini, A., and Schein, J. (1998) Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J. Clin. Psychiatry 59 (Suppl. 3), 3-7.
12. Cohn, J. N., Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., Gottlieb, S. O., McGrew, F., 3rd, DeMets, D. L., and White, B. G. (1998) A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone trial investigators. N. Engl. J. Med. 339, 1810-1816.
13. Ellrodt, A. G., Murata, G. H., Riedinger, M. S., Stewart, M. E., Mochizuki, C., and Gray, R. (1984) Severe neutropenia associated with sustained-release procainamide. Ann. Intern. Med. 100, 197-201.
14. Liu, Z. C., and Uetrecht, J. P. (1995) Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J. Pharmacol. Exp. Ther. 275, 1476-1483.
15. Uetrecht, J. P., Zahid, N., and Whitfield, D. (1994) Metabolism of vesnarinone by activated neutrophils: Implications for vesnarinone-induced agranulocytosis. J. Pharmacol. Exp. Ther. 270, 865-872.
16. Uetrecht, J. P., and Zahid, N. (1991) N-Chlorination and oxidation of procainamide by myeloperoxidase: toxicological implications. Chem. Res. Toxicol. 4, 218-222.
17. Uetrecht, J. P. (1985) Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J. Pharmacol. Exp. Ther. 232, 420-425.
18. Busch, F. W., Tillmann, A., Becker, E. W., Owsianowski, M., and Berg, P. A. (1992) The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), on bone-marrow progenitor cells and peripheral lymphocytes. Eur. J. Clin. Pharmacol. 42, 629-633.
19. Weigmann, H., and Hiemke, C. (1992) Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 583, 209-216.
20. Gardner, I., Leeder, J. S., Chin, T., Zahid, N., and Uetrecht, J. P. (1998) A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol. 53, 999-1008.
21. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
22. Maggs, J. L., Williams, D., Pirmohamed, M., and Park, B. K. (1995) The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J. Pharmacol. Exp. Ther. 275, 1463-1475.
23. Freeman, R. W., Uetrecht, J. P., Woosley, R. L., Oates, J. A., and Harbison, R. D. (1981) Covalent binding of procainamide in vitro and in vivo to hepatic protein in mice. Drug Metab. Dispos. 9, 188-192.
24. Cohen, S. D., Pumford, N. R., Khairallah, E. A., Boekelheide, K., Pohl, L. R., Amouzadeh, H. R., and Hinson, J. A. (1997) Selective protein covalent binding and target organ toxicity. Toxicol. Appl. Pharmacol. 143, 1-12.
25. Rubin, R. L., Uetrecht, J. P., and Jones, J. E. (1987) Cytotoxicity of oxidative metabolites of procainamide. J. Pharmacol. Exp. Ther. 242, 833-841.
26. Hill, C. M., Lunec, J., Griffiths, H. R., and Herbert, K. E. (1995) Characterization of tumour necrosis factor alpha release by human granulocytes in response to procainamide challenge. Biochem. Pharmacol. 49, 1837-1849.
27. Williams, D. P., Pirmohamed, M., Naisbitt, D. J., Maggs, J. L., and Park, B. K. (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: Possible role in agranulocytosis. J. Pharmacol. Exp. Ther. 283, 1375-1382.
28. Gardner, I., Zahid, N., MacCrimmon, D., and Uetrecht, J. P. (1998) A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol. Pharmacol. 53, 991-998.
29. Gillette, J. R. (1974) A perspective on the role of chemically reactive metabolites of foreign compounds in toxicity. II. Alterations in the kinetics of covalent binding. Biochem. Pharmacol. 23, 2927-2938.
30. Pirmohamed, M., Williams, D., Madden, S., Templeton, E., and Park, B. K. (1995) Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther. 272, 984-990.
31. Kellner, M., Wiedemann, K., Krieg, J. C., and Berg, P. A. (1993) Toxic hepatitis by clozapine treatment. Am. J. Psychiatry 150, 985-986.
32. Adams, L. E., Roberts, S. M., Donovan-Brand, R., Zimmer, H., and Hess, E. V. (1993) Study of procainamide hapten-specific antibodies in rabbits and humans. Int. J. Immunopharmacol. 15, 887-897.